The global leukemia therapeutic market is anticipated to grow at a considerable CAGR of 7.3% during the forecast period.  Leukemia is a chronic disease that is prevalent across the globe and has been putting an economic burden on the globe. It has a considerable presence in developed and developing economies such as the US, UK, Spain, China, India, and Korea. The market is expected to perform significantly due to advancements in leukemia therapeutics, R&D, funding from government and private players, and successful clinical trials. However, the high cost of leukemia therapeutics and less awareness among key regions is a concern for the growth of the leukemia therapeutics market in emerging economies. The diagnosis of leukemia includes health and physical exam, complete blood count, biopsy and bone marrow aspiration, blood chemistry test, cytochemistry, ct scan, x-ray, MRI, ultrasound, and so on. The key therapies of leukemia therapeutics include chemotherapy, stem cell transplant, radiation therapy, targeted therapy, watchful waiting, and supportive therapy. New product developments launched by market players are further aid in market growth. For instance, in November 2021, Pelco Therapeutics SA entered into a strategic partnership with Hyloris Pharmaceuticals SA. The partnership results in developing and commercializing a novel Plecoid agent to improve the effectiveness of chemotherapy in patients with Acute Myeloid Leukaemia (AML), and small cell lung cancer (SCLC).  

Despite the benefits of leukemia treatment products, side effects and adverse reaction associated, raise of the chemotherapy, which leads to hair loss, skin problem, tiredness, and other related side effects results in hampering the growth of the market. Moreover, significant R&D investments in cancer treatment, clinical, and life science research by the government will create lucrative opportunities for the market during the forecast period.

Impact of COVID-19 Pandemic on Global Leukemia Therapeutic Market 

The COVID-19 pandemic has affect the healthcare sector in a negative way. Most healthcare companies have their manufacturing units in countries such as the US, and UK, where the impact of the COVID-19 pandemic was on the urge. Moreover, according to the U.K. Coronavirus Cancer Monitoring Project (UKCCMP), the patients with blood cancers, leukemia, lymphoma, and multiple myeloma were more susceptible to COVID-19. All cancer patients should be on high alert due to their increased risk of experiencing poorer outcomes if they are infected by the virus. Cancer, and certain cancer treatments, can wreak havoc on the immune system, a side effect that’s especially worrisome during a pandemic. 

Segmental Outlook 

The global leukemia therapeutic market is segmented based on type, and treatment type. Based on type the market is bifurcated into acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia. Based on treatment type, the market is sub-segmented into chemotherapy, immunotherapy, targeted therapy, and others. 

Global Leukemia Therapeutic Market Share by Drug, 2021 (%)

The Acute Lymphoblastic Leukemia Drugs Segment is predicted to Account for the Largest Revenue Share in the Global Leukaemia Therapeutic Market 

Based on drug types, the acute lymphoblastic leukemia drugs segment is accounted to hold the prominent market share during the forecast period. Hereditary links, genetic defects, and possibly radiation or chemical exposures are listed among the most significant risk factors for the growth of the segment. Acute lymphoblastic leukemia is predominantly a disease that occurs in childhood, but it affects adults as well. According to the American Cancer Society, the risk for developing acute leukemia is highest in children younger than 5 years of age. The risk then declines slowly until the mid-20s and begins to rise again slowly after age 50. Overall, around 4 of every 10 cases of acute leukemia are in adults, a total of 6,660 new cases of acute leukemia registered of which 3,740 are males and 2,920 are females, in January 2022. 

Regional Outlooks

The global leukemia therapeutic market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America).  The Europe region has been estimated to reach at the highest CAGR during the forecast period from 2022-2028. The market is propelling in the region, mainly due to factors such as increased innovation and R&D in the oncology sector and a rapidly growing number of biotechnology firms.    

Global Leukemia Therapeutic Market Growth, by Region 2021-2028

The Asia-Pacific is the Fastest Growing Region for Global Leukaemia Therapeutic Market  

The Asia-Pacific is anticipated to be the fastest-growing region in the coming year. On account of the rising number of people suffering from leukemia, the global leukemia therapeutics market is driven by technological developments and advancements in research in the field of blood cancer diagnostics. Moreover, government initiatives and various programs aimed at increasing cancer awareness among the people, which is further expected to boost the growth of the global leukemia therapeutics market in the Asia-Pacific region. The Asia-Pacific region is home to 60% of the world’s population and accounts for about 50% of total global cancer incidence, there were an estimated 8.8m new cancer cases and 5.5m cancer deaths in Asia in 2018, according to the International Agency for Research on Cancer (IARC). 

Market Players Outlook

The major companies serving the global leukemia therapeutic market are Alcon Vision LLC, Bausch Health Co. Inc., Johnson & Johnson, STAAR Surgical Co. ZEISS Co., Eyevensys, Glaukos Corp., Hoya Corp., Layerbio Morcher GmbH, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in February 2022, the US health regulator has approved a therapy developed by Johnson and Johnson along with its China focused partner Legend Biotech. This therapy delivers new therapeutic options and drive towards for the elimination of cancer. 

The Report Covers

• Market value data analysis of 2021 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.Key companies operating in the global leukemia therapeutic market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.